Assessing Nasal Obstruction Improvement in Dupilumab-Treated Patients With Active Anterior Rhinomanometry: A Preliminary Study.

Francesco Giombi, Gian Marco Pace, Giulia Mari, Michele Cerasuolo, Giulio Sandri, Luca Cerri, Enrico Heffler, Giovanni Paoletti, Francesca Puggioni, Giuseppe Mercante, Giuseppe Spriano, Luca Malvezzi
{"title":"Assessing Nasal Obstruction Improvement in Dupilumab-Treated Patients With Active Anterior Rhinomanometry: A Preliminary Study.","authors":"Francesco Giombi, Gian Marco Pace, Giulia Mari, Michele Cerasuolo, Giulio Sandri, Luca Cerri, Enrico Heffler, Giovanni Paoletti, Francesca Puggioni, Giuseppe Mercante, Giuseppe Spriano, Luca Malvezzi","doi":"10.1177/01455613251350508","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To objectively assess nasal flow obstruction improvement through anterior active rhinomanometry (AAR) in patients with severe chronic rhinosinusitis with nasal polyps treated with dupilumab.</p><p><strong>Methods: </strong>Dupilumab-treated patients were evaluated at baseline (T0), 3rd month (T1) and 6th month (T2) after therapy initiation by AAR, and nasal airway resistances were measured using the Rinopocket ED200 system™. The Lund-Mackay Score (LMS), the Nasal Polyp Score (NPS) and the Lund-Kennedy Score (LKS) were assessed. Also, patients were required to fill in the Nasal Obstruction Symptom Evaluation scale, the 22-Item Sinonasal Outcome Test and the Visual Analogue Scale for sinonasal symptoms.</p><p><strong>Results: </strong>Twenty-one patients (n = 21) were included. By T1, both inspiratory and expiratory resistances, as well as total nasal resistance, showed a significant reduction. At T2, these improvements were sustained but did not differ significantly from T1. Patient-reported outcomes followed a similar trend, showing marked improvement at T1 but no further significant changes at T2. Conversely, endoscopic and radiologic outcomes (NPS, LKS, LMS) demonstrated significant improvements across all timepoints.</p><p><strong>Conclusions: </strong>This preliminary study shows the rapid effectiveness of dupilumab in relieving nasal obstruction. Interestingly, while endoscopic and radiologic assessments showed ongoing improvement at each time point, nasal airway resistance measured with AAR did not significantly decrease beyond the initial 3 months of treatment.</p>","PeriodicalId":93984,"journal":{"name":"Ear, nose, & throat journal","volume":" ","pages":"1455613251350508"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ear, nose, & throat journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/01455613251350508","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To objectively assess nasal flow obstruction improvement through anterior active rhinomanometry (AAR) in patients with severe chronic rhinosinusitis with nasal polyps treated with dupilumab.

Methods: Dupilumab-treated patients were evaluated at baseline (T0), 3rd month (T1) and 6th month (T2) after therapy initiation by AAR, and nasal airway resistances were measured using the Rinopocket ED200 system™. The Lund-Mackay Score (LMS), the Nasal Polyp Score (NPS) and the Lund-Kennedy Score (LKS) were assessed. Also, patients were required to fill in the Nasal Obstruction Symptom Evaluation scale, the 22-Item Sinonasal Outcome Test and the Visual Analogue Scale for sinonasal symptoms.

Results: Twenty-one patients (n = 21) were included. By T1, both inspiratory and expiratory resistances, as well as total nasal resistance, showed a significant reduction. At T2, these improvements were sustained but did not differ significantly from T1. Patient-reported outcomes followed a similar trend, showing marked improvement at T1 but no further significant changes at T2. Conversely, endoscopic and radiologic outcomes (NPS, LKS, LMS) demonstrated significant improvements across all timepoints.

Conclusions: This preliminary study shows the rapid effectiveness of dupilumab in relieving nasal obstruction. Interestingly, while endoscopic and radiologic assessments showed ongoing improvement at each time point, nasal airway resistance measured with AAR did not significantly decrease beyond the initial 3 months of treatment.

评估dupilumab治疗的积极前鼻测量患者鼻塞改善:一项初步研究。
目的:通过前路活动性鼻测压法(AAR)客观评价dupilumab治疗重度慢性鼻窦炎合并鼻息肉患者鼻流阻塞的改善情况。方法:采用AAR在基线(T0)、治疗开始后第3个月(T1)和第6个月(T2)对dupilumab治疗的患者进行评估,并使用Rinopocket ED200系统™测量鼻气道阻力。采用隆德-麦凯评分(LMS)、鼻息肉评分(NPS)和隆德-肯尼迪评分(LKS)进行评估。并要求患者填写鼻塞症状评定量表、22项鼻窦结局测试和鼻窦症状视觉模拟量表。结果:纳入21例患者(n = 21)。到T1时,吸气和呼气阻力以及总鼻阻力均明显降低。在T2时,这些改善得以持续,但与T1相比没有显著差异。患者报告的结果遵循类似的趋势,在T1时表现出明显的改善,但在T2时没有进一步的显著变化。相反,内镜和放射预后(NPS、LKS、LMS)在所有时间点均显示出显著改善。结论:本初步研究显示dupilumab在缓解鼻塞方面的快速有效性。有趣的是,虽然内镜和放射学评估显示在每个时间点持续改善,但用AAR测量的鼻气道阻力在治疗的最初3个月之后并没有显著降低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信